Pemoline - Generic Drug Details
✉ Email this page to a colleague
What are the generic sources for pemoline and what is the scope of freedom to operate?
Pemoline
is the generic ingredient in two branded drugs marketed by Abbott, Actavis Elizabeth, Teva Pharms, Fosun Pharma, Mallinckrodt, Vintage Pharms, and Watson Labs, and is included in ten NDAs. Additional information is available in the individual branded drug profile pages.There are seven drug master file entries for pemoline.
Summary for pemoline
US Patents: | 0 |
Tradenames: | 2 |
Applicants: | 7 |
NDAs: | 10 |
Drug Master File Entries: | 7 |
Raw Ingredient (Bulk) Api Vendors: | 45 |
Clinical Trials: | 5 |
Patent Applications: | 5,270 |
Formulation / Manufacturing: | see details |
DailyMed Link: | pemoline at DailyMed |
Recent Clinical Trials for pemoline
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Medical University of Vienna | Phase 2 |
California Pacific Medical Center Research Institute | Phase 2 |
Sheba Medical Center | N/A |
Medical Subject Heading (MeSH) Categories for pemoline
US Patents and Regulatory Information for pemoline
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Actavis Elizabeth | PEMOLINE | pemoline | TABLET;ORAL | 075595-002 | Feb 28, 2000 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
Abbott | CYLERT | pemoline | TABLET, CHEWABLE;ORAL | 017703-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
Vintage Pharms | PEMOLINE | pemoline | TABLET;ORAL | 075328-003 | Apr 19, 2000 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |